This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Reports Positive Findings Backing RDN System
by Zacks Equity Research
Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.
Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays
by Zacks Equity Research
In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $112.52, marking a +1.42% move from the previous day.
Medtronic (MDT) Completes 1st Patient Implant of Implantable TNM
by Zacks Equity Research
Medtronic's (MDT) TITAN 2 study will examine the safety and efficacy of the implantable TNM device in people with OAB.
The Zacks Analyst Blog Highlights Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co.
by Zacks Equity Research
Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co. have been included in this Analyst Blog.
Medtronic (MDT) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Stocks to Focus on With MedTech M&A Scaling New Heights
by Riya Anand
MedTech stocks like Owens & Minor (OMI), Thermo Fisher (TMO) and Medtronic (MDT) are prudent investment choices given their long-term growth potential with recent M&A deals.
Is Medtronic (MDT) a Suitable Value Investor Stock Now?
by Zacks Equity Research
Let's see if Medtronic (MDT) stock is a good choice for value-oriented investors right now from multiple angles.
Top Analyst Reports for Amazon, NVIDIA & JPMorgan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), NVIDIA Corporation (NVDA) and JPMorgan Chase & Co. (JPM).
Medtronic (MDT) Boosts Surgical Robotics Wing With New Deal
by Zacks Equity Research
According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) system.
Here's Why You Should Hold on to Medtronic (MDT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.
Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise
by Zacks Equity Research
Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.
Medtronic (MDT) to Gain From New Reimbursement Program for CGM
by Zacks Equity Research
Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.
4 Stocks in Spotlight With AI Making Inroads in MedTech
by Riya Anand
MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.
Medtronic (MDT) Gains Market Share Despite COVID Headwinds
by Zacks Equity Research
In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.
Top Stock Reports for Mastercard, Wells Fargo & United Parcel Service
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Wells Fargo & Company (WFC), and United Parcel Service, Inc. (UPS).
Medtronic's (MDT) NuVent Balloon to Strengthen ENT Business
by Zacks Equity Research
Medtronic's (MDT) Nuvent balloons are one-time use devices featuring a flexible balloon section that allows customized placement based on patient anatomy.
Company News for Feb 23, 2022
by Zacks Equity Research
Companies in The News Are: MDT,CNP,WLK,CVI
Medtronic's (MDT) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Medtronic (MDT) registers organic growth in the Cardiovascular, Neuroscience and Diabetes segments in Q3.
Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.
Medtronic (MDT) Q3 Earnings Top Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.74% and 1.60%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $103.91, marking a +1.56% move from the previous day.
Medtronic (MDT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $106.09 in the latest trading session, marking a +1.8% move from the prior day.